Literature DB >> 28232508

Pulmonary hypertension in ARDS: inflammation matters!

Laura C Price1, S John Wort1.   

Abstract

Entities:  

Keywords:  ARDS; Primary Pulmonary Hypertension

Mesh：

Year:  2017        PMID： 28232508     DOI： 10.1136/thoraxjnl-2016-209199

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  6 in total

1.  Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?

Authors:  B Jiang; S Liang; G Liang; H Wei
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-10       Impact factor: 3.507

Review 2.  Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course.

Authors:  Rashika Bansal; Sriram Gubbi; Ranganath Muniyappa
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

Review 3.  Adult congenital heart disease and the COVID-19 pandemic.

Authors:  Robert M Radke; Tim Frenzel; Helmut Baumgartner; Gerhard-Paul Diller
Journal:  Heart       Date:  2020-06-10       Impact factor: 5.994

4.  Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.

Authors:  John J Ryan; Lana Melendres-Groves; Roham T Zamanian; Ronald J Oudiz; Murali Chakinala; Erika B Rosenzweig; Mardi Gomberg-Maitland
Journal:  Pulm Circ       Date:  2020-04-29       Impact factor: 3.017

Review 5.  Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets.

Authors:  Harry Karmouty-Quintana; Rajarajan A Thandavarayan; Steven P Keller; Sandeep Sahay; Lavannya M Pandit; Bindu Akkanti
Journal:  Int J Mol Sci       Date:  2020-10-29       Impact factor: 5.923

6.  Comparison of two porcine acute lung injury models: a post-hoc analysis.

Authors:  René Rissel; Miriam Renz; Katja Mohnke; Julian Riedel; Katharina Ritter; Alexander Ziebart; Robert Ruemmler; Erik K Hartmann; Jens Kamuf
Journal:  Intensive Care Med Exp       Date:  2022-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.